Internacional

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point.

Por Redacción Sinergia Empresarial · 06 de julio de 2026 · 1 min

This Profitable Autoimmune Biotech Trades Near A High And A Buy Point.

Biotech stock Argenx (ARGX) broke out of a cup-with-handle base and recently hit an all-time high. For that and other reasons, the maker of a drug to treat the autoimmune disease myasthenia gravis is Monday's pick for IBD 50 Growth Stocks To Watch. The Netherlands-based company turned profitable in 2024. Earnings grew 53% in 2025, and analysts expect profit to rise…

Sinergia Empresarial continuará el seguimiento de esta información sobre this Profitable Autoimmune Biotech Trades Near A High And A Buy Point y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.

Sigue leyendo

Más en Internacional

Internacional

'You have to be careful': Personal finance expert warns travelers about the major mistake they're making at the airport

'You have to be careful': Personal finance expert warns travelers about the major mistake they're making at the airport.

05 de julio de 2026 · 3 min

Internacional

Robert Kiyosaki says the 'everything bubble' is about to pop in the 'worst crash in history.' Protect yourself now

Robert Kiyosaki says the 'everything bubble' is about to pop in the 'worst crash in history.' Protect yourself now.

05 de julio de 2026 · 2 min

Internacional

Beware the top-heavy economy

Beware the top-heavy economy. Supersize capital flows are reshaping business—and building risk

06 de julio de 2026 · 1 min